Results from the phase 2 TROPION-Lung05 trial published in the Journal of Clinical Oncology revealed that among 137 patients given 6 mg/kg of dato-DXd every 21 days for pretreated NSCLC, the confirmed ORR was 35.8% (95% CI, 27.8%-44.4%), including 32.8% of patients experiencing a partial response and 2.9% having a complete response
Sign in with the email used at checkout to leave a verified review.
Factors affecting the timeline include injury severity, consistency of use, proper dosing, overall health, and concurrent therapies
Nicotinamide N-methyltransferase (NNMT) is a cytoplasmic enzyme that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM, the universal methyl donor) to nicotinamide (the NAD + salvage precursor), producing 1-methylnicotinamide and S-adenosyl-L-homocysteine
Maintain sterile handling practices after first puncture
Always start low and watch response